Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment.
BACKGROUND
The impact of an inflammatory response, as well as interactions between the immune and nervous systems, are rapidly assuming major roles in neurodegenerative disease and injury. However, it is now appreciated that the exact nature of such responses can differ with each type of insult and interaction. More recently, neuroinflammation and the associated cellular response of microglia are being considered for their contribution to neurotoxicity of environmental agents; yet, so far, the inclusion of inflammatory end points into neurotoxicity assessment have relied primarily on relatively limited measures or driven by in vitro models of neurotoxicity.


OBJECTIVE
To present background information on relevant biological considerations of neuroinflammation and the microglia response demonstrating the complex integrative nature of these biological processes and raising concern with regards to translation of effects demonstrated in vitro to the in vivo situation. Specific points are addressed that would influence the design and interpretation of neuroinflammation with regards to neurotoxicology assessment.


CONCLUSIONS
There is a complex and dynamic response in the brain to regulate inflammatory processes and maintain a normal homeostatic level. The classification of such responses as beneficial or detrimental is an oversimplification. Neuroinflammation should be considered as a balanced network of processes in which subtle modifications can shift the cells toward disparate outcomes. The tendency to overinterpret data obtained in an isolated culture system should be discouraged. Rather, the use of cross-disciplinary approaches to evaluate several end points should be incorporated into the assessment of inflammatory contributions to the neurotoxicity of environmental exposures.
Harry
Gaylia Jean
GJ
National Institute of Environmental Health Sciences, National Institutes of Health, Neurotoxicology Group, Laboratory of Neurobiology, Department of Health and Human Services, Research Triangle Park, NC 27709, USA. harry@niehs.nih.gov
Kraft
Andrew D
AD
D000818:Animals; D018929:Cell Culture Techniques; D015536:Down-Regulation / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D018836:Inflammation Mediators / Q000378:metabolism; D017628:Microglia / Q000378:metabolism*; D008954:Models, Biological; D009420:Nervous System / Q000378:metabolism / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000378:metabolism; D020258:Neurotoxicity Syndromes / Q000175:diagnosis* / Q000209:etiology
D018836:Inflammation Mediators
J Neuroimmunol. 1996 May;66(1-2):115-23
8964905
J Comp Neurol. 2007 Oct 20;504(6):716-29
17722035
J Comp Neurol. 2006 Jul 10;497(2):199-208
16705680
Eur J Neurosci. 1999 Sep;11(9):3359-64
10510203
Trends Neurosci. 2006 Sep;29(9):506-10
16859761
J Neuroimmunol. 2006 Nov;180(1-2):71-87
16996144
Exp Neurol. 1998 Mar;150(1):30-9
9514820
Neurotox Res. 2007 Dec;12(4):215-32
18201950
Int Rev Neurobiol. 2007;82:235-46
17678964
J Neurosci. 2002 Apr 15;22(8):3025-32
11943805
Trends Neurosci. 2005 Nov;28(11):571-3
16165228
Prog Neurobiol. 2005 Jun;76(2):126-52
16115721
Int J Dev Neurosci. 1996 Oct;14(6):707-19
8960978
J Leukoc Biol. 1999 Apr;65(4):407-8
10204567
J Neurochem. 2008 Jul;106(1):271-80
18384650
Eur J Neurosci. 1996 Dec;8(12):2582-90
8996807
Science. 2000 Dec 1;290(5497):1768-71
11099416
Neurogenetics. 2004 Jun;5(2):95-108
15042428
Brain Behav Immun. 2000 Dec;14(4):288-304
11120597
J Comp Neurol. 2006 Dec 1;499(4):565-82
17029271
J Cell Mol Med. 2008 Jun;12(3):762-80
18363841
J Neurosci. 2005 Oct 5;25(40):9275-84
16207887
Neurochem Int. 2006 Jul;49(2):145-53
16759751
Trends Neurosci. 1996 Aug;19(8):312-8
8843599
Front Biosci. 2008 May 01;13:3423-38
18508444
J Neuroimmunol. 2007 Feb;183(1-2):125-32
17229471
J Neuroinflammation. 2004 Jul 30;1(1):14
15285801
Nature. 2008 Feb 7;451(7179):720-4
18256671
J Neurosci Res. 2000 Oct 1;62(1):146-55
11002296
Eur J Neurosci. 1993 Feb 1;5(2):122-7
7903184
Glia. 1996 Dec;18(4):319-31
8972800
J Neuroimmune Pharmacol. 2006 Jun;1(2):127-37
18040779
Rev Environ Health. 2006 Apr-Jun;21(2):105-17
16898674
Neuroscience. 1991;43(2-3):335-47
1922776
Mol Med. 2003 May-Aug;9(5-8):125-34
14571320
Glia. 2006 May;53(7):688-95
16482523
J Neuroimmunol. 2002 Sep;130(1-2):1-9
12225883
FASEB J. 2006 Apr;20(6):670-82
16581975
J Clin Invest. 2005 Feb;115(2):233-6
15690080
Neurotherapeutics. 2007 Oct;4(4):571-9
17920538
J Neurosci. 2005 Mar 16;25(11):2952-64
15772355
Rev Neurosci. 2002;13(3):221-42
12405226
J Neurosci Res. 1998 Aug 1;53(3):361-7
9698164
Glia. 1993 Jan;7(1):34-40
8423060
Eur J Neurosci. 1999 May;11(5):1657-67
10215919
J Neuroimmunol. 2005 Mar;160(1-2):92-101
15710462
J Exp Med. 1993 Apr 1;177(4):1181-6
8459212
J Immunol. 2001 Jun 15;166(12):7496-503
11390503
J Immunol. 2002 Sep 1;169(5):2264-73
12193691
J Biol Chem. 1997 Mar 21;272(12):7786-91
9065441
Glia. 1998 Jan;22(1):72-85
9436789
Neuroreport. 2007 Mar 26;18(5):425-9
17496797
Glia. 2002 Jan;37(1):43-52
11746782
Neuroscience. 1994 Nov;63(2):471-87
7891859
Neuron. 2004 Feb 19;41(4):535-47
14980203
Neuropathol Appl Neurobiol. 1994 Aug;20(4):392-8
7808590
Neurology. 1995 Jun;45(6 Suppl 6):S39-43
7783910
Neuroscience. 2000;96(1):131-9
10683418
Nat Rev Immunol. 2007 Feb;7(2):161-7
17220915
J Neurosci Res. 1999 Jan 1;55(1):1-8
9890428
Toxicol Appl Pharmacol. 1995 Jun;132(2):325-33
7785060
Trends Neurosci. 2007 Nov;30(11):596-602
17950926
Eur J Neurosci. 1997 Apr;9(4):863-6
9153594
Immunopharmacology. 2000 Aug;49(1-2):171-86
10904116
Brain Res. 2007 Feb 2;1131(1):17-28
17161388
Nature. 2002 Dec 19-26;420(6917):853-9
12490958
J Neurochem. 2002 Dec;83(6):1309-20
12472885
Brain Behav Immun. 2004 Sep;18(5):407-13
15265532
Brain Behav Immun. 2007 May;21(4):367-73
17234380
Glia. 2003 Sep;43(3):274-80
12898706
J Neurochem. 2003 Dec;87(5):1193-203
14622099
Dev Neurosci. 2004 Jan-Feb;26(1):30-7
15509896
J Neurosci. 2004 Jul 21;24(29):6457-65
15269255
Immunol Rev. 2006 Oct;213:48-65
16972896
Prog Neurobiol. 2008 Mar;84(3):211-33
18262323
Glia. 1999 Dec;28(3):265-71
10559785
Glia. 2001 Mar 1;33(3):256-66
11241743
J Neurosci Res. 2004 Aug 15;77(4):540-51
15264224
Neuroscience. 2000;96(2):427-38
10683583
Mol Psychiatry. 1997 Mar;2(2):96-8
9106225
Neurosci Lett. 2001 Jul 20;307(3):171-4
11438391
Toxicol Appl Pharmacol. 1998 Jun;150(2):271-6
9653057
Trends Neurosci. 1999 Jul;22(7):295-9
10370250
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20
1438191
Trends Immunol. 2007 Jan;28(1):12-8
17129764
Toxicol Appl Pharmacol. 2002 May 1;180(3):205-18
12009860
Exp Neurol. 2000 Apr;162(2):290-6
10739635
Nat Neurosci. 2005 Jun;8(6):752-8
15895084
Brain Res. 2008 Feb 15;1194:8-20
18191113
Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):547-56
10571416
J Neurosci Res. 2003 Feb 15;71(4):583-90
12548715
J Neurosci. 2008 Feb 27;28(9):2221-30
18305255
Acta Neurochir (Wien). 1998;140(3):275-9
9638265
Neurobiol Aging. 2001 Nov-Dec;22(6):799-809
11754986
Science. 1988 Jan 15;239(4837):290-2
3276004
Glia. 2002 Nov;40(2):195-205
12379907
J Hirnforsch. 1992;33(4-5):471-6
1479187
Glia. 2001 Nov;36(2):191-9
11596127
Trends Neurosci. 2006 Feb;29(2):68-74
16406093
J Neuroinflammation. 2005 Nov 15;2:25
16285888
J Neurosci. 2007 Mar 7;27(10):2596-605
17344397
Glia. 2003 Dec;44(3):219-31
14603463
J Neuroimmunol. 2002 Sep;130(1-2):86-99
12225891
Neuroscience. 2002;115(1):307-20
12401343
J Neurochem. 2008 Jul;106(1):281-98
18373618
Glia. 2004 Jan 15;45(2):208-12
14730714
Ann Neurol. 2001 Jun;49(6):808-10
11409436
Brain Res. 2008 Jun 24;1216:78-86
18495090
J Neurochem. 2005 Apr;93(1):206-20
15773920
Science. 2005 May 27;308(5726):1314-8
15831717
Hippocampus. 2005;15(5):656-64
15889405
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837-42
12119423
J Neurosci. 1998 Aug 15;18(16):6358-69
9698327
J Biol Chem. 2003 Apr 25;278(17):14747-52
12584205
Nat Rev Immunol. 2005 Aug;5(8):629-40
16034365